Endothelial Effects of VEGF Inhibition In Vivo in Man

Cardiovascular Diseases Clinical Trial

— ENDEAVOUR  

Official title:

Novel Cancer Chemotherapeutics and the Vasculature: Endothelial Effects of VEGF Inhibition In Vivo in Man

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03557190
• Other study ID #: GN16CA026
• Status: Completed
• Start date: December 1, 2016
• Est. completion date: July 1, 2018

Study information

• Verified date: November 2019
• Source: NHS Greater Glasgow and Clyde
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Recent developments in chemotherapy, particularly VEGF-inhibitor (VEGFI) drugs, have markedly improved the prognosis of patients with cancer. However, these drugs frequently cause high blood pressure (hypertension) which can lead to heart attacks, heart failure and stroke and can limit their use for cancer treatment.

Endothelin-1 is a hormone that causes blood vessels to tighten and may contribute to high blood pressure associated with VEGFI drugs. Blocking the effects of endothelin-1 may therefore reduce or prevent VEGFI-associated blood pressure changes, although this has never been tested in humans.

Our long-term goal is to assess the protective effects of endothelin-1 blocker drugs in patients treated with VEGFI. Before doing so, we must better explore whether VEGFIs cause blood vessel narrowing and if endothelin-1 blockers prevent this. We will assess this in healthy volunteers using a special technique called 'forearm plethysmography'. We will examine the effect of VEGFI on blood flow and also the effect of simultaneous administration of endothelin-1 blockers. These will be given at doses that produce local effects in the arm without affecting the rest of the body.

These studies study will show whether endothelin-1 blockers may help treat VEGFI-associated hypertension to enable more patients safely to receive vital cancer treatments.

Description:

Developments in chemotherapy have improved the prognosis for patients with cancer.1,2 Angiogenesis is essential for tumour growth and metastasis and vascular endothelial growth factor (VEGF) is fundamental to this process.3,4 Chemotherapeutic VEGF inhibitor (VEGFI) drugs have revolutionised therapy and improved the prognosis and survival of patients with previously untreatable malignancies.1,2 Blood pressure elevation is a common complication that occurs in up to 80% of patients treated with VEGFI and almost all patients have an absolute increase in blood pressure, with 30-60% developing frank hypertension.1,5 Patients are at risk of acute hypertensive complications, including stroke, acute coronary syndrome or reversible leukoencephalopathy and the development of VEGFI-associated hypertension may mandate the premature discontinuation of these important anti-cancer therapies. Those who survive their cancer are at risk of developing end-organ damage leading to ischaemic heart disease, heart failure, renal failure and stroke.1,5 Indeed, with substantially increased cancer survivorship patients often survive long enough to allow cardiovascular morbidity to take precedence over their initial cancer diagnosis.

Mechanisms contributing to the development of VEGFI-associated hypertension may include endothelial dysfunction, capillary rarefaction and vascular remodelling.1,5 Endothelin-1 (ET-1) is a potent endogenous vasoconstrictor and is strongly implicated in the pathogenesis of hypertension and endothelial dysfunction. 3,6,7 However, the effects of VEGFI on endothelial function and the role of ET-1 in VEGFI-associated hypertension are incompletely defined. Indeed, there is a paucity of information on mechanisms contributing to VEGFI-induced hypertension and our study will address this key issue.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: July 1, 2018
• Est. primary completion date: July 1, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• healthy volunteer male

• aged between 18 and 64 years

Exclusion Criteria:

• Unable to provide written, informed consent

• Unable or unwilling to attend for study assessments

• Current involvement in a clinical trial

• Severe or significant co-morbidity including:

• Hypertension

• Hyperlipidaemia

• Cerebrovascular disease

• Ischaemic heart disease or heart failure

• Arial fibrillation/flutter

• Venous or arterial thrombotic/thromboembolic event

• Renal failure

• Hepatic failure

• Use of any prescription medication or non-steroidal anti-inflammatory drugs within the 3 days prior to vascular assessments

• Cigarette smoker or tobacco use

• Recreational drug use

• History of anaemia

• History of cancer

• History of macular degeneration

• Ongoing inflammatory, infective or autoimmune disease

• Live vaccination received in the 3 months before the study, or expected to be required in the 6 months after the study

• Unable or unwilling to use contraception with female partners in the 6 months after the study

• BMI > 35 kg/m2

• Unable to avoid blood donation for 1 week after the study

Related Conditions & MeSH terms

• Cardiovascular Diseases

Locations

Country	Name	City	State
United Kingdom	Queen Elizabeth University Hospital	Glasgow

Sponsors (2)

Lead Sponsor	Collaborator
NHS Greater Glasgow and Clyde	University of Glasgow

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in forearm blood flow	Study drugs will be infused intra-arterially and forearm arterial blood flow assessed using forearm venous occlusion plethysmography expressed as ml per 100 ml of forearm volume per minute	105 minutes
Secondary	Change in plasma concentration of t-PA	Change in plasma concentration of t-PA measured as units/mL	105 minutes
Secondary	Change in plasma concentration of PAI-1	Change in plasma concentration of PAI-1 measured as units/mL	105 minutes